Is Rinvoq Approved for Ulcerative Colitis?
Yes, Rinvoq (upadacitinib) is FDA-approved for adults with moderately to severely active ulcerative colitis when other treatments fail or are not tolerated. The approval came in March 2022 for induction and maintenance therapy, based on data from three phase 3 trials (U-ACHIEVE, U-ACCOMPLISH, U-ACHIEVE Maintenance) showing higher clinical remission rates than placebo—42% vs. 16% at week 8 for induction, and 52% vs. 20% at week 52 for maintenance.[1][2]
How Does Rinvoq Work for Ulcerative Colitis?
Rinvoq is a selective JAK inhibitor that blocks Janus kinase enzymes involved in inflammatory signaling. In ulcerative colitis, it reduces gut inflammation by targeting cytokines like IL-6 and IL-23, leading to symptom relief such as reduced rectal bleeding and stool frequency.[1]
Who Qualifies for Rinvoq Treatment?
It's indicated for adults 18+ with moderate-to-severe disease unresponsive to TNF blockers, conventional therapies, or corticosteroids. Not approved for children or mild cases. Dosing starts at 45 mg daily for 8 weeks (induction), then 15-30 mg maintenance based on response.[1][2]
Common Side Effects and Risks
Patients report upper respiratory infections (18%), anemia (7%), fever (6%), acne (6%), and herpes zoster (3-4%). Serious risks include infections (e.g., TB reactivation), blood clots, heart issues, cancer, and gastrointestinal tears—black box warnings apply. Requires TB screening and monitoring; avoid live vaccines.[1][3]
How Does Rinvoq Compare to Other UC Drugs?
| Drug | Class | Remission Rate (Week 8 Induction) | Key Differences |
|------|--------|-----------------------------------|-----------------|
| Rinvoq | JAK inhibitor (oral) | 42% [2] | Faster onset than biologics; oral convenience but higher infection risk |
| Stelara (ustekinumab) | IL-12/23 inhibitor (IV/subQ) | 16-24% [4] | Lower infection risk; slower onset |
| Entyvio (vedolizumab) | Integrin inhibitor (IV) | 31% [4] | Gut-selective; safer for systemic infections |
| Humira (adalimumab) | TNF blocker (subQ) | 18% [4] | Cheaper generics emerging; less effective post-failure |
Rinvoq often works after TNF failure, but head-to-head data is limited.[2][4]
Cost and Access for Ulcerative Colitis Patients
List price is about $6,000-$7,000 monthly before discounts; AbbVie patient assistance covers copays under $5,000/year for eligible insured patients. Biosimilars unlikely soon due to patents expiring 2033-2039 (check DrugPatentWatch.com for updates).[5][6]
When Might Patents Expire?
Core patents on Rinvoq expire in 2033 (U.S. composition-of-matter), with others to 2039. No major challenges filed yet, delaying generic entry.[6]
Sources
[1]: Rinvoq Prescribing Information (FDA)
[2]: NEJM: U-ACHIEVE Trial
[3]: FDA Safety Warnings
[4]: Clinical Trial Comparisons (ACG Guidelines)
[5]: GoodRx Pricing
[6]: DrugPatentWatch: Rinvoq Patents